Market Data
Market Cap₹7,801.29 Cr.
52W High₹1,919.25
Current Price₹1,792.45
52W Low₹944
Down from 52W High6.6 %
Face Value₹10
Performance
ROCE12.2 %
ROE7.45 %
EPS (TTM)₹8.77
EPS Prev Qtr₹6.44
EPS Last Year₹7.26
EBITDA Qtr₹84.69 Cr.
Book Value₹386
Financial Health
Debt/Equity0.34
Debt/Profit3.38
Total Assets₹3,600.263 Cr.
Promoter Holding52.4 %
Earning Power7.39 %
Valuation
Stock P/E46.53
Industry P/E33.81
Price to Book4.64
Price to Sales1.09
Graham Number₹578.63
Key Metrics
Face Value
₹10
About Entero Healthcare Solutions Ltd
Healthcare · Pharmaceuticals
Entero Healthcare Solutions Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹7,801.29 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a healthy promoter holding of 52.4%, indicating strong control and alignment of interests.
- The company has a manageable debt-to-equity ratio of 0.34, suggesting a relatively conservative capital structure.
- The Return on Capital Employed (ROCE) of 12.2% shows efficient utilization of capital employed to generate profits.
Weaknesses
- The P/E ratio of 62.48 is relatively high, indicating that the stock may be overvalued compared to its earnings.
- The P/B ratio of 4.66 suggests that the market values the company at a premium over its book value.
- The Return on Equity (ROE) of 9.97% is moderate, indicating room for improvement in generating returns on shareholders' equity.
- The company does not currently offer a dividend yield, which may be a concern for income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 1,570.95 | 1,706.52 | 1,909.93 | 1,940.5 |
| ↳ QoQ Growth | - | +8.6% | +11.9% | +1.6% |
| Expenses | 1,518.72 | 1,648.54 | 1,838.68 | 1,855.81 |
| Operating Profit | 52.23 | 57.98 | 71.25 | 84.69 |
| OPM % | 3.32% | 3.4% | 3.73% | 4.36% |
| Other Income | 4.79 | 4.61 | 4.01 | 3.01 |
| Interest | 12.4 | 14.01 | 17.31 | 20.57 |
| Depreciation | 9.83 | 9.8 | 14.79 | 12.31 |
| EBITDA | 62.06 | 67.78 | 86.04 | 97 |
| EBITDA Margin % | 3.95% | 3.97% | 4.5% | 5% |
| Profit Before Tax | 44.63 | 40.4 | 57.95 | 67.12 |
| Tax % | 17.99% | 16.14% | 22.12% | 22.45% |
| Net Profit | 36.6 | 33.88 | 45.13 | 52.05 |
| ↳ QoQ Growth | - | -7.4% | +33.2% | +15.3% |
| EPS | 7.26 | 6.35 | 6.44 | 8.77 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 43.51 | 43.511 |
| Reserves | 1680.64 | 1638.677 |
| Borrowings | 385.23 | 566.68 |
| Other Liabilities | 593.14 | 1351.4 |
| Total Liabilities | 2702.52 | 3600.263 |
| Fixed Assets | 132.06 | 960.485 |
| CWIP | 0 | 0 |
| Investments | 57.56 | 129.89 |
| Other Assets | 2512.9 | 2509.89 |
| Total Assets | 2702.52 | 3600.263 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 96.202 |
| Cash from Investing Activity | -303.058 |
| Cash from Financing Activity | 123.659 |
| Net Cash Flow | -83.197 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 52.42% | 52.42% | 52.42% | 52.4% |
| FIIs % | 14.67% | 5.14% | 4.03% | 4.37% |
| DIIs % | 9.64% | 16.42% | 16.62% | 15.48% |
| Public % | 9.36% | 11.56% | 12.25% | 13.05% |
| No. of Shareholders | 36,334 | 40,332 | 39,084 | 39,709 |
Major Shareholders (>1%)
- Orbimed Asia Iii Mauritius LimitedPromoter and Promoter Group38.00%
- Surbhi Singh(prasid Uno Family Trust)Public Shareholding10.45%
- Prabhat AgrawalPromoter and Promoter Group9.26%
- Prem SethiPromoter and Promoter Group5.15%
As of 2026-06-30View all shareholders →